Document Detail

Resiquimod, a topical drug for viral skin lesions and skin cancer.
MedLine Citation:
PMID:  23205468     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions.
AREAS COVERED: Studies on genital herpes, hepatitis C and actinic keratosis (AK) as well as papers of molecular activities of resiquimod were identified by a PubMed search. Although effective against genital HSV-2 in animal models, development of topical resiquimod for the treatment of recurrent genital herpes in humans was stopped due to inconsistent results in clinical trials. Reduction of HCV viral load was achieved by oral application but was associated with unacceptable side effects. Topical treatment of AK was well tolerated and effective with clearance rates higher compared to imiquimod. The molecular mode of action underlying the clinical efficacy primarily depends on cytokine induction in TLR7/8 expressing dendritic cells in the skin.
EXPERT OPINION: Topical resiquimod was shown to be a safe and effective treatment option for AK and appears to have potential as a treatment modality for patients with extended skin areas affected with AK (field cancerization). Resiquimod may also have potential for the therapy or prevention of epithelial viral infections.
Thomas Meyer; Christian Surber; Lars E French; Eggert Stockfleth
Related Documents :
15467158 - Retrotransposition-competent human line-1 induces apoptosis in cancer cells with intact...
7588628 - Dna damage in human b cells can induce apoptosis, proceeding from g1/s when p53 is tran...
10554678 - Hpv-16 e7 but not e6 oncogenic protein triggers both cellular immunosuppression and ang...
12644898 - Apoptosis induction in human cancer cells by sungucine from strychnos icaja root.
11817608 - Hla class ii tetramers: tools for direct analysis of antigen-specific cd4+ t cells.
15865608 - Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimula...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-12-04
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  22     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-12     Completed Date:  2013-05-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  149-59     Citation Subset:  IM    
University of Hamburg, Institute of Medical Microbiology, Virology and Hygiene, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Antineoplastic Agents / administration & dosage*,  adverse effects,  pharmacokinetics
Antiviral Agents / administration & dosage*,  adverse effects,  pharmacokinetics
Imidazoles / administration & dosage*,  adverse effects,  pharmacokinetics
Skin Diseases / drug therapy*
Treatment Outcome
Virus Diseases / drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Antiviral Agents; 0/Imidazoles; V3DMU7PVXF/resiquimod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Investigation of Hypoxia-induced Myocardial Injury Dynamics in a Tissue Interface Mimicking Microflu...
Next Document:  Toxicity of Functionalized Single-Walled Carbon Nanotubes on Soil Microbial Communities: Implication...